Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the ...

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Gossamer Bio (GOSS – Research Report) today and set a price target of ...

Custom MIPSA antigen libraries can also be created to address specific research needs. About Infinity Bio Infinity Bio, Inc.

Instil Bio, Inc. (NASDAQ:TIL) recently traded higher on the back of analyst raising their price target on shares because of how much the PD-1/VEGF bispecific antibody space is heating up.

Instil Bio Inc. and Immuneonco Biopharmaceuticals Inc. laid out their global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510 (IMM-2510) in front-line non-small-cell lung cancer ...

Company remains committed to its mission to become a leader in developing differentiated product candidates targeting immune, inflammatory and ...

SOMERVILLE, Mass. (AP) — SOMERVILLE, Mass. (AP) — Bluebird Bio Inc. (BLUE) on Friday reported a first-quarter loss of $69.8 million, after reporting a profit in the same period a year earlier. On a ...

Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, ...

SAN FRANCISCO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th ...

ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, ...